Article
Oncology
Tamara Hofer, Matteo Rossi, Susanna Carboni, Wilma Di Berardino Besson, Dorothee von Laer, Guido Wollmann, Madiha Derouazi, Marie-Laure Santiago-Raber
Summary: Developing new therapeutic cancer vaccines is crucial to combat tumor escape after conventional therapies in certain types of cancer. The study's multi-epitope vaccine can induce potent anti-tumor immune responses in various tumor models, laying a foundation for cancer immunotherapy.
Article
Pharmacology & Pharmacy
Alexis A. Ellis, Sean M. Geary, Aliasger K. Salem
Summary: Heterologous prime-boost vaccines consisting of a microparticle formulation and an adenoviral vaccine were used in this study to investigate their effect on antigen-specific immune responses. The results showed that this prime-boost vaccine significantly enhanced cellular immune responses and conferred a significant survival advantage in a prophylactic animal tumor model.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Immunology
Delphine C. Malherbe, Lo Vang, Jason Mendy, Philip T. Barnette, David A. Spencer, Jason Reed, Bettie W. Kareko, D. Noah Sather, Shilpi Pandey, Constantinos K. Wibmer, Harlan Robins, Deborah H. Fuller, Byung Park, Samir K. Lakhashe, James M. Wilson, Michael K. Axthelm, Ruth M. Ruprecht, Penny L. Moore, Jonah B. Sacha, Ann J. Hessell, Jeff Alexander, Nancy L. Haigwood
Summary: A comparative vaccine challenge study in rhesus macaques showed that the combination vaccination with SAd7+Protein was superior in reducing viral seeding in tissues. Despite the lack of protection from infection, the higher antibody responses elicited in this vaccine group may help limit tissue viral seeding.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Ramiro A. Ramirez-Valdez, Faezzah Baharom, Ahad Khalilnezhad, Sloane C. Fussell, Dalton J. Hermans, Alexander M. Schrager, Kennedy K. S. Tobin, Geoffrey M. Lynn, Shabnam Khalilnezhad, Florent Ginhoux, Benoit J. Van den Eynde, Carol Sze Ki Leung, Andrew S. Ishizuka, Robert A. Seder
Summary: A heterologous prime-boost vaccination strategy using a self-assembling peptide nanoparticle TLR-7/8 agonist vaccine and a chimp adenovirus vaccine is found to enhance CD8 T cells and induce tumor regression. Intravenous administration of the chimp adenovirus has higher CD8 T cell responses compared to intramuscular administration. This strategy represents a translatable paradigm for enhancing anti-tumor immunity in humans.
Article
Immunology
Ching-Fen Shen, Yi-Chen Fu, Tzong-Shiann Ho, Po-Lin Chen, Nan-Yao Lee, Bo-Yang Tsai, Pei-Jane Tsai, Wen-Chien Ko, Ching-Chuan Liu, Chao-Min Cheng, Chi-Chang Shieh
Summary: This study investigated the immunological response of healthcare workers who received a heterologous prime-boost COVID vaccination. The results showed that the heterologous vaccination enhanced both humoral and cellular immunity, and exhibited a strong response to the Omicron variant.
CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Louise Benning, Maximilian Toellner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kaelble, Paula Reichel, Mirabel Buylaert, Julia Grenz, Gerald Ponath, Katrin Klein, Martin Zeier, Caner Susal, Paul Schnitzler, Christian Morath, Claudius Speer
Summary: This study demonstrates that heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination is safe and induces a strong and broad humoral response in healthy individuals.
Article
Immunology
Hadar Marcus, Emily Thompson, Yan Zhou, Michael Bailey, Mitzi M. Donaldson, Daphne A. Stanley, Clement Asiedu, Kathryn E. Foulds, Mario Roederer, Juan Moliva, Nancy J. Sullivan
Summary: Heterologous prime-boost immunization regimens have been shown to protect non-human primates against Ebola virus, with different strategies inducing either CD4(+) or CD8(+) T-cell responses while maintaining high levels of antibodies. A single DNA prime immunization can generate a stable memory response that can be boosted 3 years later by rAd5. This suggests that DNA/rAd5 prime-boost provides a flexible platform for generating desirable T-cell memory responses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Adrian Rice, Mohit Verma, Emily Voigt, Peter Battisti, Sam Beaver, Sierra Reed, Kyle Dinkins, Shivani Mody, Lise Zakin, Shiho Tanaka, Brett Morimoto, C. Anders Olson, Elizabeth Gabitzsch, Jeffrey T. Safrit, Patricia Spilman, Corey Casper, Patrick Soon-Shiong
Summary: The study assessed the enhanced immune responses in CD-1 mice by heterologous vaccination with two different nucleic acid-based COVID-19 vaccines. It was found that one vaccine showed better T-cell and humoral responses, and the sera from vaccinated mice exhibited high neutralizing activity against various strains of the virus.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Xingxing Li, Ling Wang, Jingjing Liu, Enyue Fang, Xiaohui Liu, Qinhua Peng, Zelun Zhang, Miao Li, Xinyu Liu, Xiaohong Wu, Danhua Zhao, Lihong Yang, Jia Li, Shouchun Cao, Yanqiu Huang, Leitai Shi, Hongshan Xu, Yunpeng Wang, Yue Suo, Guangzhi Yue, Jianhui Nie, Weijin Huang, Wenjuan Li, Yuhua Li
Summary: Combining intramuscular and intranasal vaccination routes can result in more potent immune responses. In a mouse study, a prime-boost protocol with intramuscular priming and intranasal boosting showed the highest levels of antibodies and T-cell responses. This study provides important reference data for assessing adenovirus-based COVID-19 vaccination schemes.
EMERGING MICROBES & INFECTIONS
(2022)
Article
Immunology
Shinji Morisaki, Hideya Onishi, Takafumi Morisaki, Makoto Kubo, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Shinichiro Nakagawa, Kenta Tsujimura, Sachiko Yoshimura, Poh Yin Yew, Kazuma Kiyotani, Yusuke Nakamura, Masafumi Nakamura, Takanari Kitazono, Takashi Morisaki
Summary: Through analysis of four patients, we found that intranodal vaccination with hybrid neoantigen-pulsed DCs successfully induced a strong immune response and provided insight into the mechanisms of action, suggesting future directions in neoantigen vaccine design.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Engineering, Biomedical
Xing Chen, Xiang Ling, Jiaxuan Xia, Ying Zhu, Longlong Zhang, Yuwei He, Anni Wang, Guolong Gu, Bo Yin, Jianxin Wang
Summary: The cytomembrane-derived delivery platform is a promising biomimetic strategy for oncotherapy. By fusing mature dendrosomes with redox-responsive nanoparticles, durable and reliable tumor inhibition can be achieved, along with enhanced immunogenicity and immunocyte differentiation. Combination with aPD-L1 further enhances the antitumor effect.
BIOACTIVE MATERIALS
(2022)
Article
Immunology
Natalie Heinen, Corinna Sophie Marheinecke, Clara Bessen, Arturo Blazquez-Navarro, Toralf Roch, Ulrik Stervbo, Moritz Anft, Carlos Plaza-Sirvent, Sandra Busse, Mara Kloehn, Jil Schrader, Elena Vidal Blanco, Doris Urlaub, Carsten Watzl, Markus Hoffmann, Stefan Poehlmann, Matthias Tenbusch, Eike Steinmann, Daniel Todt, Carsten Hagenbeck, Gert Zimmer, Wolfgang Ekkehard Schmidt, Daniel Robert Quast, Nina Babel, Ingo Schmitz, Stephanie Pfaender
Summary: Studies have shown that both homologous and heterologous prime-boost-boost vaccination strategies can induce robust humoral and T cell-mediated immunity against the Omicron variant of SARS-CoV-2. These findings can guide policy decisions.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Riddha Das, Elias A. Halabi, Ina R. Fredrich, Juhyun Oh, Hannah M. Peterson, Xinying Ge, Ella Scott, Rainer H. Kohler, Christopher S. Garris, Ralph Weissleder
Summary: This study developed a hybrid nanoparticle platform that can effectively eradicate tumors and generate long-lasting anti-tumor immunity. Stimulating dendritic cells through a multi-pronged approach allows for dose reductions of drugs while enhancing their efficacy.
Article
Oncology
James McAuliffe, Hok Fung Chan, Laurine Noblecourt, Ramiro Andrei Ramirez-Valdez, Vinnycius Pereira-Almeida, Yaxuan Zhou, Emily Pollock, Federica Cappuccini, Irina Redchenko, Adrian V. S. Hill, Carol Sze Ki Leung, Benoit J. Van den Eynde
Summary: A novel vaccine was developed to induce potent CD8(+) T cell response, and when combined with anti-PD-1, it showed improved therapeutic efficacy in murine tumor models expressing P1A antigen. The vaccine promoted CD8(+) T cell infiltration into tumors and drove inflammation in the tumor microenvironment, converting 'cold' tumors into 'hot' tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Jie Zhang, Biao Fan, Guoliang Cao, Wenping Huang, Fuhao Jia, Guangjun Nie, Hai Wang
Summary: This study developed a personalized DC-mimicking nanovaccine for stimulating TAAs-specific T cell populations. By inducing BMDCs maturation and delivering TAAs through nanostructures, the nanoDCs efficiently generated potent antigen-specific T cell responses, leading to inhibition of tumor growth and metastases formation.
ADVANCED MATERIALS
(2022)